Speaker illustration

Mr Ruslan Horblyuk

New York (United States of America)

Contemporary results from EHR study of real-world bleeding risk among elderly and overall non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban and warfarin

Event: ESC Congress 2016

Topic: Atrial fibrillation (AF)

Session: New trends in antithrombotic therapy for atrial fibrillation

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb